Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
499.65
+8.31 (1.69%)
Jun 29, 2026, 4:00 PM EDT - Market closed
Vertex Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 33 analysts polled by S&P Global, Vertex Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $548.69. The average 1-year stock price forecast is 9.81% higher than the current stock price, while the lowest is $330 (-33.95%) and the highest is $641 (+28.29%).
Price Target: $548.69 (+9.81%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Vertex Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 19 | 21 | 22 | 21 | 21 | 21 |
| Buy | 4 | 4 | 5 | 5 | 6 | 6 |
| Hold | 6 | 5 | 4 | 5 | 5 | 5 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 31 | 32 | 33 | 32 | 33 | 33 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $546 → $641 | Buy | Maintains | $546 → $641 | +28.29% | Jun 29, 2026 |
Unknown Analyst Raymond James No rating | Raymond James | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Jun 25, 2026 |
| Needham | Needham | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Jun 24, 2026 |
| Barclays | Barclays | Buy Maintains $615 | Buy | Maintains | $615 | +23.09% | Jun 22, 2026 |
| Citi | Citi | Buy Maintains $585 | Buy | Maintains | $585 | +17.08% | Jun 16, 2026 |
Financial Forecast
Revenue This Year
13.04B
from 12.00B
Increased by 8.64%
Revenue Next Year
14.27B
from 13.04B
Increased by 9.42%
EPS This Year
19.15
from 18.40
Increased by 4.05%
EPS Next Year
21.47
from 19.15
Increased by 12.15%
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 13.1B | ||
| Avg | 13.0B | ||
| Low | 13.0B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 9.2% | ||
| Avg | 8.6% | ||
| Low | 7.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 20.73 | ||
| Avg | 19.15 | ||
| Low | 18.42 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 12.7% | ||
| Avg | 4.1% | ||
| Low | 0.1% |